Product Images Roweepra

This is a prescription medication called Roweepra. It contains 1000mg of evetiracetam USP per tablet. It should be stored in a tight and light-resistant container with a child-resistant closure. The prescribing information will contain dosage recommendations. It is important to dispense the medication guide to the patient. It has a manufacturing license number and a product code. This medicine should be dispensed after verification. Store this medicine between 20-26°C, with excursions allowed between 15-30°C (59°-86°F).*

This appears to be a description of medication in tablet form called Levitiracetam, with a recommended dosage of 1000mg. A medication guide is also mentioned that should be dispensed to each patient. The packaging includes 60 tablets and is manufactured by a company called Rev202018. There is also a reference number provided. The first line mentions an unvarnished area, but it is unclear what this refers to in relation to the medication.*

This is a description of a medication called Roweepra, specifically the 500mg Levetiracetam tablets. The medication is produced by pharmaceutical companies, W Farma and Torrent Pharmaceuticals. The tablets come in a container that is resistant to light and moisture. The prescription information should be given to each patient who takes the medication. It is recommended to store this medication at room temperature, between 20-25°C (88-77°F).*

Product Name: Unvarnished Quantity: 120 tablets Dosage: 750mg Active Ingredient: Levetiracetom tablets USP Caution: Verify product dispensed carefully. Dispense the accompanying modification guide to each patient, Rx only.*

This is a table showing the percentage of patients who were given Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The number of patients for each group is also mentioned.*

This is a table showing various percentages for patients in a clinical trial for a drug called Levetiracetam versus a placebo. The table displays percentages in increments of 5% ranging from 20% to 45% for an unknown metric related to the patients. Additionally, there is a mention of the number of patients in the placebo and Levetiracetam groups, which are 97 and 101 respectively. There are also some non-readable characters such as "@", "%" and "®".*

This is not-available as the given text does not have sufficient information to generate a useful description. The text contains only some numbers and names of treatments which cannot be interpreted without additional context.*

This text shows the percentage 45.2% with no clear indication of its meaning. It also shows two groups, one with a sample size of 1 labeled as Placebo and another with a sample size of 79 labeled as Levetiracetam. There is not enough information to determine the context of this text.*